Japanese pharmaceutical company Takeda is considering carrying out global clinical trials in India to accelerate the introduction of its innovative treatments in the nation, its head in India informed Reuters. The decision arises as India's clinical trials market grows, fueled by varied patient demographics, cost-effectiveness, and an increasingly broad hospital network. Grand View Research anticipates the market will surpass Rs. 17,456 crore (US$ 2 billion) by the year 2030. The general manager of Takeda India, Ms. Annapurna Das, remarked that the company is assessing chances to utilize India’s clinical trial ecosystem and is receptive to collaborations with local academic institutions, healthcare providers, and technology companies to promote innovation. Takeda aims to incorporate India’s research and development ecosystem into its worldwide pipeline while enhancing patient access to treatments in oncology, neuroscience, gastrointestinal health, and inflammation. Takeda aims to introduce several important treatments in India over the next two to three years, which includes a lung cancer medication this year and a dengue vaccine in collaboration with local producer Biological E., pending approval from India's drug regulatory authority. The firm has recently set up an innovation hub in Bengaluru, growing its workforce from just over 500 to 750 staff, focusing on artificial intelligence (AI), data science, engineering, and design to aid its worldwide digital transformation. This strategic emphasis on India highlights Takeda’s enduring dedication to the nation as a market for growth. It highlights the growing significance of India in worldwide pharmaceutical research and innovation.